H Lundbeck A/S

H Lundbeck A/S EBIT Margin

The EBIT Margin (Operating Margin) of H Lundbeck A/S (LUN.CO) as of Oct 15, 2026 is 26.05 %. In the previous year, EBIT Margin (Operating Margin) was 14.86 % — a change of 75.28% (higher).

EBIT Margin

26.05 %

YoY

75.28%

Last updated:

EBIT Margin (Operating Margin) of H Lundbeck A/S is 2025 26.05 % . EBIT Margin (Operating Margin) of H Lundbeck A/S was 2024 14.86 % . It decreases by 75.28% higher compared to the previous year.

H Lundbeck A/S's operating (EBIT) margin stands at 26.0%, up from 12.3% several years earlier.

The H Lundbeck A/S EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
29.66 DKK
Jan 1, 2019
20.79 DKK
Jan 1, 2020
11.26 DKK
Jan 1, 2021
12.33 DKK
Jan 1, 2022
15.63 DKK
Jan 1, 2023
16.05 DKK
Jan 1, 2024
14.86 DKK
Jan 1, 2025
26.05 DKK
The H Lundbeck A/S EBIT Margin history
YEAREBIT MarginYoY
26.05 %+75.28%
14.86 %-7.38%
16.05 %+2.65%
15.63 %+26.75%
12.33 %+9.48%
11.26 %-45.81%
20.79 %-29.91%
29.66 %+15.95%
25.58 %+74.47%
14.66 %-132.77%
-44.73 %-6,185.18%
0.74 %+601.43%
0.10 %-5.82%
0.11 %-47.51%
0.21 %-6.77%
0.23 %+9.36%
0.21 %-0.26%
0.21 %-15.05%
0.25 %+26.83%
0.19 %—
Access this data via the Eulerpool API

H Lundbeck A/S Stock analysis

What does H Lundbeck A/S do? H Lundbeck A/S is a Danish company that was founded in 1915 by Hans Lundbeck. Since its inception, the company has focused on researching and developing medications that improve the lives of people with neuropsychiatric disorders. Lundbeck's business model is based on a clear strategy and a strong focus on the research and development of pharmaceuticals. The company has four main therapy areas: depression, anxiety disorders, Alzheimer's, and Parkinson's. Lundbeck products are sold in over 100 countries worldwide and are known for their effectiveness and high quality. Over the years, Lundbeck has also focused on developing innovative treatment methods, including research on new drugs and therapies based on neurotransmitters such as serotonin, dopamine, and norepinephrine. With the acquisition of Alder BioPharmaceuticals in 2019, Lundbeck also expanded its portfolio in the field of migraine therapy. Some of Lundbeck's most well-known products include Lexapro, Cipralex, Selincro, Abilify Maintena, and Brintellix. These medications are used in the treatment of depression, anxiety disorders, alcoholism, bipolar disorders, and migraines. In addition to selling medications, Lundbeck also provides training and support for healthcare professionals and patients. Lundbeck is also distinguished by its commitment to social engagement and works closely with nonprofit organizations to raise awareness of neuropsychiatric disorders. The company has also launched various programs to improve access to medical care in particularly affected regions. In 2020, Lundbeck exceeded 18,000 employees worldwide and had a revenue of 16.6 billion Danish kroner. Lundbeck is listed on NASDAQ OMX Copenhagen and is controlled by the Lundbeck Foundation, which holds over 70% of the company's ownership. In summary, Lundbeck is a leading company in the field of neuropsychiatric medicine and is dedicated to improving the lives of people with these serious disorders. The company has made a name for itself through its successful research and development of therapies and medications, as well as its strong focus on social engagement and corporate social responsibility. H Lundbeck A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about H Lundbeck A/S stock

EBIT Margin (Operating Margin) of H Lundbeck A/S is 26.05 % in 2025.

EBIT Margin (Operating Margin) of H Lundbeck A/S changed from 14.86 % to 26.05 %, representing a 75.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) H Lundbeck A/S since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s H Lundbeck A/S with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

Margins — H Lundbeck A/S

All Key Metrics — H Lundbeck A/S